Advanced Search

Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2005 September;30(3) > Minerva Endocrinologica 2005 September;30(3):101-20



A Journal on Endocrine System Diseases

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118

Frequency: Quarterly

ISSN 0391-1977

Online ISSN 1827-1634


Minerva Endocrinologica 2005 September;30(3):101-20


Insulin resistance syndrome. A review

Vasudevan A. R., Garber A. J.

Insulin is a hormone and a growth factor that elicits a myriad variety of metabolic and mitogenic cellular actions. Insulin resistance (IR) could occur with any of the effects of insulin, even though it usually refers to its ability to stimulate glucose uptake in insulin-sensitive peripheral tissues such as fat and muscle. IR as it applies to the glucose-insulin relationship is distinctly different from the clinical concept of an IR syndrome, which applies to a cluster of metabolic disorders (type 2 diabetes mellitus [T2DM], central obesity, dyslipidemia, hypertension, increased prothrombotic and antifibrinolytic factors/ hypercoagulability and a predilection for heart disease). The rising obesity epidemic portends great significance, as it is associated with a high prevalence of IR. We review the etiopathogenesis of IR, the clinical spectrum, and review the clinical data on the management of IR.

language: English

Full text temporarily not available online. Contact us  REPRINTS

top of page